Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment upon receiving U.S. Food and Drug Administration (FDA) approval for the drug. In March 2020, the FDA accepted the New Drug Application (NDA) for vibegron in overactive bladder (OAB) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020.